NCT04495179 - A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

November 1, 2021

Study Completion Date

August 8, 2022

Conditions

Progressive Metastatic Castrate-Resistant Prostate Cancer

Interventions

DRUG

AZD4635

Subjects will receive AZD4635 orally daily

DRUG

Durvalumab

Subjects will receive intravenous durvalumab every 4 weeks for Arm A and every 3 weeks for Arm B.

DRUG

Cabazitaxel

Subjects will receive intravenous cabazitaxel every 3 weeks

Trial Locations (16)

2930

Research Site, Brasschaat

8035

Research Site, Barcelona

9000

Research Site, Ghent

10408

Research Site, Goyang-si

27157

Research Site, Winston-Salem

28034

Research Site, Madrid

30318

Research Site, Atlanta

33076

Research Site, Bordeaux

33612

Research Site, Tampa

63110

Research Site, St Louis

94805

Research Site, Villejuif

95817

Research Site, Sacramento

06351

Research Site, Seoul

06591

Research Site, Seoul

08041

Research Site, Barcelona

08907

Research Site, Hospitalet deLlobregat